Skip to main content
logo
enGene Therapeutics Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
1.770
-0.080 (-4.32%)
At close: Aug 20, 2026, 4:00 PM EDT
1.770
0.00 (0.00%)
After-hours: Aug 20, 2026, 4:35 PM EDT

enGene Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Nov - Oct.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Market Capitalization
119369451343160-
Market Cap Growth
-37.63%-18.18%31.50%113.74%--
Enterprise Value
-107199218438--
Last Close Price
1.857.218.8521.7010.15-

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
PB Ratio
0.492.201.664.73-13.33-
P/TBV Ratio
0.462.201.664.73--

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Debt / Equity Ratio
0.130.190.090.14-2.350.41
Net Debt / Equity Ratio
-0.88-0.97-0.78-0.99-0.65-0.85
Net Debt / EBITDA Ratio
1.711.323.442.77-0.410.48
Net Debt / FCF Ratio
2.021.614.342.86-0.440.46
Quick Ratio
12.176.1316.3315.954.263.93
Current Ratio
12.576.3016.8716.254.434.20
Return on Equity (ROE)
-52.59%-53.28%-31.96%-330.60%--
Return on Assets (ROA)
-28.86%-28.90%-19.56%-29.38%-62.37%-
Return on Capital Employed (ROCE)
-46.40%-65.00%-21.00%-31.90%-103.30%-134.40%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Earnings Yield
-106.98%-31.78%-12.22%-29.13%-15.24%-
FCF Yield
-93.94%-27.29%-10.91%-7.31%-11.06%-
Buyback Yield / Dilution
-25.52%-35.30%-5355.08%-5.72%81.61%-28.93%
SEC Filings: 10-K · 10-Q